Moleculin Biotech Secures Hong Kong Patent for Annamycin Through June 2040
Moleculin Biotech secured Hong Kong patent No. 40073244 on its liposomal Annamycin reconstitution method, extending exclusivity through June 25, 2040 under co-ownership with The University of Texas System. Patent addition complements global IP portfolio across 12 jurisdictions and bolsters positioning ahead of Phase 3 data due later this quarter.
1. Hong Kong Patent Details
Moleculin Biotech announced issuance of Hong Kong patent No. 40073244 for its proprietary liposomal Annamycin reconstitution method, extending exclusivity through June 25, 2040. The patent is jointly owned with The University of Texas System.
2. Global IP Portfolio Expansion
This approval builds on Moleculin’s established intellectual property portfolio, which now includes allowed, issued, or granted patents in the United States, Australia, Canada, China, Europe, India, Israel, Japan, Mexico, Singapore, and Taiwan, reinforcing global protection of Annamycin.
3. Strategic Implications and Phase 3 Timeline
Securing rights in Hong Kong positions Moleculin in a key Asian oncology market and strengthens its global exclusivity strategy ahead of the expected Phase 3 clinical data release later this quarter, which could be a catalyst for future commercialization efforts.